On April 28, 2011, the U.S. FDA approved Abiraterone acetate to be used in Combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.

Abiraterone acetate is used in treatment of prostate cancer.

This medication is to be taken as prescribed by your doctor. Abiraterone acetate is administered orally (by mouth) and the recommended dose is 1000mg (two tablets) once a day. This medication is not to be taken with food and must be consumed whole without breaking it.

The common side effects of Abiraterone acetate are bone fracture, indigestion, blood in urine, rash, diarrhea, high fat levels in the blood, chest pain, irregular heartbeat, rapid heart rate, urinary tract infection, fluid in the legs or feet, high BP, and low blood potassium levels in the body (serious).

Abiraterone acetate is unsafe during pregnancy as it may cause harm to the unborn baby. This medication must not be taken with food. If you are lactose intolerant inform your doctor before starting treatment with this medication as it contains lactose. Inform your doctor if you are on a salt control diet as it contains sodium.

Inform your doctor if you have liver disease, high blood pressure, heart failure or low blood potassium levels, and high sugar levels. Effective contraception is to be followed while being treated with Abiraterone acetate. Inform your doctor about any medications you are taking before starting treatment with this medication.

Abiraterone acetate is to be taken once daily without food. This medication must be taken after two hours of taking food. Once the medication is taken, food must be eaten only after at least one hour.

1. Centocor Ortho Biotech Inc, US Food and drug administration, [ Revised date: APR 2011] [ Accessed date: 26 MAY 2022], https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf 
2. Janssen- Cilag International NV, Electronics Medicine Compendium (emc), [Revised date: SEP 2021] [ Accessed date: 26 MAY 2022]  https://www.medicines.org.uk/emc/files/pil.2381.pdf 
3. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Natural products in cancer chemotherapy: hormones and related agents, 12th edition, 2011, 1707 - 1709. 

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.